New treatment option for endometrial cancer shows promise in phase II trial

The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a phase III trial.

Measles is coming back. My sister Marcie isn’t

At the end of February 1960, my healthy, precocious sister Marcie was halfway through the fourth grade when she contracted measles from a classmate who

May 7, 2024

Anthos to stop factor XI trial in atrial fibrillation early after ‘overwhelming benefit’

Anthos Therapeutics announced Monday morning that it is stopping a Phase II study of its next-generation anticoagulant abelacimab in atrial fibrillation as a result of

September 19, 2023

House committee advances PRV reauthorization, but timing on final passage remains ‘murky’

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.